Gene therapy and neurodevelopmental disorders

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

With a number of recent clinical successes, gene therapy is quickly becoming a realistic treatment option for neurological disorders. Advancements in global central nervous system (CNS) gene delivery, in particular, have accelerated to the point that treatments for neurological disorders such as lysosomal storage diseases seem within reach. Other neurodevelopmental disorders, such as Rett Syndrome, Fragile X, and autism still face significant obstacles to overcome before a viable human gene therapy can be considered. This review focuses on the most common CNS gene delivery vehicle, adeno-associated virus (AAV), and the current state of AAV vector design and delivery for CNS gene therapy. Relevant examples of gene therapy studies for neurodevelopmental disorders, as well as outstanding challenges, are discussed. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.

Original languageEnglish (US)
Pages (from-to)136-142
Number of pages7
JournalNeuropharmacology
Volume68
DOIs
StatePublished - May 1 2013

Fingerprint

Genetic Therapy
Dependovirus
Central Nervous System
Nervous System Diseases
Lysosomal Storage Diseases
Rett Syndrome
Autistic Disorder
Genes
Neurodevelopmental Disorders
Therapeutics

Keywords

  • AAV
  • Angelman syndrome
  • Gene therapy
  • Lysosomal storage disease
  • Neurodevelopmental disorder
  • Rett syndrome

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Gene therapy and neurodevelopmental disorders. / Gray, Steven James.

In: Neuropharmacology, Vol. 68, 01.05.2013, p. 136-142.

Research output: Contribution to journalReview article

@article{90e5c94c509a43df81d785b2cfc3137d,
title = "Gene therapy and neurodevelopmental disorders",
abstract = "With a number of recent clinical successes, gene therapy is quickly becoming a realistic treatment option for neurological disorders. Advancements in global central nervous system (CNS) gene delivery, in particular, have accelerated to the point that treatments for neurological disorders such as lysosomal storage diseases seem within reach. Other neurodevelopmental disorders, such as Rett Syndrome, Fragile X, and autism still face significant obstacles to overcome before a viable human gene therapy can be considered. This review focuses on the most common CNS gene delivery vehicle, adeno-associated virus (AAV), and the current state of AAV vector design and delivery for CNS gene therapy. Relevant examples of gene therapy studies for neurodevelopmental disorders, as well as outstanding challenges, are discussed. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.",
keywords = "AAV, Angelman syndrome, Gene therapy, Lysosomal storage disease, Neurodevelopmental disorder, Rett syndrome",
author = "Gray, {Steven James}",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.neuropharm.2012.06.024",
language = "English (US)",
volume = "68",
pages = "136--142",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Gene therapy and neurodevelopmental disorders

AU - Gray, Steven James

PY - 2013/5/1

Y1 - 2013/5/1

N2 - With a number of recent clinical successes, gene therapy is quickly becoming a realistic treatment option for neurological disorders. Advancements in global central nervous system (CNS) gene delivery, in particular, have accelerated to the point that treatments for neurological disorders such as lysosomal storage diseases seem within reach. Other neurodevelopmental disorders, such as Rett Syndrome, Fragile X, and autism still face significant obstacles to overcome before a viable human gene therapy can be considered. This review focuses on the most common CNS gene delivery vehicle, adeno-associated virus (AAV), and the current state of AAV vector design and delivery for CNS gene therapy. Relevant examples of gene therapy studies for neurodevelopmental disorders, as well as outstanding challenges, are discussed. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.

AB - With a number of recent clinical successes, gene therapy is quickly becoming a realistic treatment option for neurological disorders. Advancements in global central nervous system (CNS) gene delivery, in particular, have accelerated to the point that treatments for neurological disorders such as lysosomal storage diseases seem within reach. Other neurodevelopmental disorders, such as Rett Syndrome, Fragile X, and autism still face significant obstacles to overcome before a viable human gene therapy can be considered. This review focuses on the most common CNS gene delivery vehicle, adeno-associated virus (AAV), and the current state of AAV vector design and delivery for CNS gene therapy. Relevant examples of gene therapy studies for neurodevelopmental disorders, as well as outstanding challenges, are discussed. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.

KW - AAV

KW - Angelman syndrome

KW - Gene therapy

KW - Lysosomal storage disease

KW - Neurodevelopmental disorder

KW - Rett syndrome

UR - http://www.scopus.com/inward/record.url?scp=84875217250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875217250&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2012.06.024

DO - 10.1016/j.neuropharm.2012.06.024

M3 - Review article

VL - 68

SP - 136

EP - 142

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -